Mignault 1995.

Methods	Design: randomised, double blind, two‐phase cross‐over 5‐day study. Prestudy titration period to establish total daily requirement Duration: 2 x 5 days + titration period Setting: not stated
Participants	Moderate to severe cancer pain N = 27 (19 included in analysis) Mean age 57 years (range 38 ‐ 69) Weight 65 (47 ‐ 104) kg
Interventions	Mm/r 8‐hourly Mm/r 12‐hourly Rescue medication: MIR
Outcomes	PI: VAS x 4 daily Adverse events: 4‐point categorical scale Participant global rating: 4‐point scale Participant preference: 4‐point scale
Notes	Oxford Quality Score: R = 1, DB = 2, W = 1. Total = 4/5
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"randomised". Method used to generate sequence not clearly stated
Allocation concealment (selection bias)	Unclear risk	Method not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"blinding maintained by administration of active and placebo tablets each day"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"blinding maintained by administration of active and placebo tablets each day"
Incomplete adverse event outcome data‐ patient level	Unclear risk	Unable to determine
Selective reporting bias for adverse events	Low risk	Incidence of 9 different AEs
Size	High risk	< 50 participants per treatment arm